CancerDrs

Prostate Cancer clinical trials in South Carolina

35 actively recruiting prostate cancer trials at 17 sites across South Carolina.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in South Carolina:
  • McLeod Regional Medical Center — Florence, South Carolina
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Self Regional Healthcare — Greenwood, South Carolina
  • Gibbs Cancer Center-Pelham — Greer, South Carolina
  • Spartanburg Medical Center — Spartanburg, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in South Carolina:
  • Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
  • Medical University of South Carolina — Charleston, South Carolina
  • Prisma Health Cancer Institute - Faris — Greenville, South Carolina
  • Saint Francis Cancer Center — Greenville, South Carolina
  • Prisma Health Cancer Institute - Eastside — Greenville, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in South Carolina:
  • Saint Francis Hospital — Greenville, South Carolina
  • Saint Francis Cancer Center — Greenville, South Carolina
  • Self Regional Healthcare — Greenwood, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in South Carolina:
  • Research Site — Myrtle Beach, South Carolina
  • Research Site — North Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in South Carolina:
  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Sponsor: Celgene
NCT ID: NCT06764485
Sites in South Carolina:
  • Hollings Cancer Center — Charleston, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in South Carolina:
  • Ralph H Johnson Veterans Hospital — Charleston, South Carolina
  • Gibbs Cancer Center and Research Institute Pelham — Greer, South Carolina
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
  • Gibbs Cancer Center — Spartanburg, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in South Carolina:
  • Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Sponsor: Pfizer
NCT ID: NCT06629779
Sites in South Carolina:
  • AUC Urologists, LLC — Myrtle Beach, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
  • Grand Strand Medical Center — Myrtle Beach, South Carolina
  • Parkway Surgery Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…

Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in South Carolina:
  • Research Site — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression f…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06855277
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in South Carolina:
  • Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
  • Gibbs Cancer Center-Pelham — Greer, South Carolina
  • Spartanburg Medical Center — Spartanburg, South Carolina
  • SMC Center for Hematology Oncology Union — Union, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Sponsor: Dendreon
NCT ID: NCT06134232
Sites in South Carolina:
  • Lowcountry Urology Institute — Charleston, South Carolina
  • Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abir…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06991556
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in South Carolina:
  • Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in South Carolina:
  • Medical University of South Carolina — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of A…

Sponsor: AstraZeneca
NCT ID: NCT07336446
Sites in South Carolina:
  • Research Site — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…

Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in South Carolina:
  • START Carolinas — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…

Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in South Carolina:
  • Ralph H. Johnson VA Medical Center, Charleston, SC — Charleston, South Carolina
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants …

Sponsor: Hoffmann-La Roche
NCT ID: NCT07287150
Sites in South Carolina:
  • Carolina Urologic Research Center — Myrtle Beach, South Carolina
View on ClinicalTrials.gov →

Showing 25 of 35 trials with sites in South Carolina. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25